Physician

Maurice J Cairoli, MD

According to 2025 Medicare claims, Maurice Cairoli, MD (NPI: 1124051107) practices hematology/oncology in the Camden, NJ market, with the plurality of this provider's patient population coming from Burlington, NJ. This provider's primary affiliated billing organization is REGIONAL CANCER CARE ASSOCIATES LLC (NPI: 1801850243; TIN: 223141761) and primary practice location at 08057-3146.

Cairoli's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 452 traditional Medicare patients, billed 78,861 HCPCS/CPT codes, and received $1,354,242 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 809 prescription claims across 181 beneficiaries totaling $3,210,446 in drug costs, led by Revlimid (Lenalidomide). 2018 DME data shows 29 claims. Open Payments data shows 1 records totaling $14. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $575,939 to $3,210,446. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $3,603 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	532	46,185	$1,069,445
2016	560	71,342	$1,521,050
2017	557	69,183	$1,468,238
2018	563	66,516	$1,212,157
2019	452	58,676	$1,312,995
2020	481	62,016	$1,459,379
2021	473	80,867	$1,536,811
2022	469	51,962	$1,130,155
2023	476	61,671	$1,213,532
2024	452	78,861	$1,354,242

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	197	811	$575,939
2016	204	794	$367,700
2017	212	845	$481,726
2018	213	976	$964,291
2019	222	1,029	$774,391
2020	236	1,084	$1,009,799
2021	231	1,145	$1,448,291
2022	195	890	$1,734,710
2023	173	748	$2,019,271
2024	181	809	$3,210,446

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	12	72	$4,976
2016	14	45	$11,028
2017	N/R	12	$1,409
2018	26	29	$4,953
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	49	228	$107
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	89	294	$104
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	318	653	$67
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	165	469	$13
96372	Injection of drug or substance under skin or into muscle	43	95	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	61	1,708	$1,078,577
Ibrance	Palbociclib	50	1,400	$780,364
Pomalyst	Pomalidomide	25	700	$562,574
Tagrisso	Osimertinib Mesylate	19	570	$306,921
Imatinib Mesylate	Imatinib Mesylate	22	720	$48,514

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$14	Genentech USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Maurice J. Cairoli, MD?

Tedicare shows public-source Medicare data for Maurice J. Cairoli, MD (NPI 1124051107), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Maurice J. Cairoli, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Maurice J. Cairoli, MD?

Maurice J. Cairoli, MD is linked to REGIONAL CANCER CARE ASSOCIATES LLC (billing NPI 1801850243) in the available physician profile data.

Does Maurice J. Cairoli, MD have Open Payments data?

Maurice J. Cairoli, MD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.